GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023

Rhea-AI Summary

On January 4, 2023, GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in the Biotech Showcase during the J.P. Morgan Healthcare Conference in San Francisco, taking place from January 9-12, 2023. CEO David Dodd will present on January 9 at 5:00 pm PST, located at the Hilton Union Square. A live webcast will be available for those unable to attend. Additionally, GeoVax management will conduct one-on-one meetings with potential partners and investors throughout the week. The company focuses on innovative therapies for cancers and infectious diseases, including COVID-19 vaccines.

ATLANTA, GA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.

Presentation Details:

Presenter:     David Dodd, Chairman & CEO

Date/Time:   January 9, 2023, 5:00 pm PST

Location:      Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level), San Francisco, CA

Website:       https://informaconnect.com/biotech-showcase/registration-options/

A webcast of the presentation will be available at the following link: https://event.webcasts.com/starthere.jsp?ei=1590568&tp_key=ddac005afe

Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:

• Biotech Showcase partnering platform: https://informaconnect.com/biotech-showcase/
• Biotechnology Innovation Organization (BIO) partnering platform: https://www.bio.org/events/bio-partnering-jpm
• Direct outreach to the Company at info@geovax.com or to its Investor Relations at govx@cg.capital

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in two Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a single-dose, COVID-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient. In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Media Relations Contact:
Gina Cestari
6 Degrees
917-797-7904
gcestari@6degreespr.com

Investor Relations Contact:
Rich Cockrell
CG Capital
404-736-3838
govx@cg.capital

FAQ

When is GeoVax presenting at the Biotech Showcase?

GeoVax Labs will present on January 9, 2023, at 5:00 pm PST.

Where is the Biotech Showcase being held?

The Biotech Showcase is at Hilton Union Square, San Francisco, CA.

Who is presenting for GeoVax at the conference?

David Dodd, the Chairman & CEO, will present on behalf of GeoVax.

What are the key therapies being developed by GeoVax?

GeoVax is developing therapies for cancers and vaccines for infectious diseases, including a COVID-19 vaccine.

How can one request a one-on-one meeting with GeoVax management?

Meetings can be arranged via the Biotech Showcase or BIO partnering platforms or by contacting the company directly.